Mounjaro vs Zepbound: Complete Comparison Guide

**Quick answer: Is Mounjaro the same as Zepbound?** Yes — both are tirzepatide, made by Eli Lilly. Mounjaro is FDA-approved for type 2 diabetes and Zepbound for weight management; the molecule is identical. When brand access or cost is a barrier, review our [compounded tirzepatide guide](/guides/mounjaro-zepbound-alternative-compounded-tirzepatide-guide). ## The Most Confusing Situation in Weight Loss Medicine If you have spent any time researching tirzepatide, you have almost certainly been confused by this: Mounjaro and Zepbound are the exact same medication, made by the same company, at the same doses, in nearly identical injection pens — but they have different names, different FDA approvals, and potentially very different price tags depending on your insurance. This is not a marketing gimmick. It is a consequence of how drug regulation works. Understanding the difference matters because it directly affects what you pay, whether your insurance covers it, and which one your doctor should prescribe. ## Same Molecule, Different Labels Both Mounjaro and Zepbound contain **tirzepatide**, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly and Company. Tirzepatide is the first medication to simultaneously activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The dual mechanism produces: - Stronger appetite suppression than GLP-1-only drugs like [semaglutide](/guides/tirzepatide-vs-semaglutide-comparison) - Improved insulin sensitivity through both GIP and GLP-1 pathways - Enhanced fat metabolism - Slowed gastric emptying for prolonged satiety What makes them different is purely regulatory. **Mounjaro** received FDA approval in May 2022 for type 2 diabetes management. **Zepbound** received FDA approval in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. ## Why Two Brand Names for the Same Drug? Pharmaceutical companies routinely seek separate approvals for different indications. Each approval requires its own clinical trial program, and each indication opens different insurance formularies and patient populations. The precedent is well established: - **Semaglutide** is sold as Ozempic (diabetes) and Wegovy (weight loss) - **Bupropion** is sold as Wellbutrin (depression) and Zyban (smoking cessation) - **Finasteride** is sold as Proscar (prostate) and Propecia (hair loss) For Eli Lilly, having Zepbound as a separate brand means they can market directly to the obesity indication, negotiate separate insurance coverage for weight management, and price the product according to the weight loss market. It also means a doctor can write a prescription for "Zepbound" that clearly communicates the intended use, simplifying insurance processing. ## Head-to-Head Comparison | Feature | Mounjaro | Zepbound | |---------|----------|----------| | **Active ingredient** | Tirzepatide | Tirzepatide | | **Manufacturer** | Eli Lilly | Eli Lilly | | **FDA approval date** | May 2022 | November 2023 | | **Approved indication** | Type 2 diabetes | Chronic weight management | | **Available doses** | 2.5, 5, 7.5, 10, 12.5, 15mg | 2.5, 5, 7.5, 10, 12.5, 15mg | | **Injection frequency** | Once weekly | Once weekly | | **Injection device** | Pre-filled pen | Pre-filled pen | | **List price** | ~$1,023/month | ~$1,060/month | | **Key clinical trials** | SURPASS program | SURMOUNT program | | **Weight loss in trials** | 15-25% (SURPASS) | 15-22.5% (SURMOUNT) | | **A1C reduction** | 1.87-2.59% | Not primary endpoint | | **Requires diabetes diagnosis** | Typically yes (for insurance) | No | ## The Clinical Trial Evidence ### Mounjaro: The SURPASS Program The SURPASS clinical trial program enrolled patients with type 2 diabetes. While the primary endpoint was glycemic control (A1C reduction), the weight loss data was remarkable: **SURPASS-1** (tirzepatide vs placebo): Patients lost 7-9.5kg (15-21 lbs) over 40 weeks, depending on dose. A1C dropped 1.87-2.07%. **SURPASS-2** (tirzepatide vs semaglutide 1mg): Tirzepatide produced superior weight loss and A1C reduction at all doses compared to semaglutide 1mg. At 15mg, patients lost an average of 12.4kg (27 lbs) vs 6.2kg (14 lbs) for semaglutide. **SURPASS-3** (tirzepatide vs insulin degludec): Tirzepatide produced weight loss of 7.5-12.9kg while insulin caused weight gain of 2.3kg. ### Zepbound: The SURMOUNT Program The SURMOUNT program specifically enrolled patients with obesity or overweight (with comorbidities) and was designed to demonstrate weight loss efficacy: **SURMOUNT-1** (tirzepatide vs placebo): The landmark trial. At 15mg, patients lost an average of 22.5% of body weight (52 lbs for the average participant) over 72 weeks. 63% of patients on the 15mg dose lost at least 20% of their body weight. **SURMOUNT-2** (tirzepatide vs placebo, in patients with diabetes + obesity): Average weight loss of 14.7% at 15mg over 72 weeks. **SURMOUNT-3** (tirzepatide after intensive lifestyle intervention): Participants who had already lost weight through diet and exercise lost an additional 18.4% with tirzepatide 15mg. **SURMOUNT-4** (maintenance study): Patients who switched from tirzepatide to placebo regained weight, while those who continued tirzepatide maintained their loss — demonstrating the importance of continued treatment. ### Bottom Line on Efficacy The drug works identically regardless of which label is on the box. The clinical trial results are consistent: tirzepatide at 15mg produces approximately 20-22.5% body weight loss in patients without diabetes and 12-15% in patients with type 2 diabetes (who tend to lose less weight on any intervention). ## Dosing: Identical for Both Both Mounjaro and Zepbound follow the same [tirzepatide dosing schedule](/guides/tirzepatide-dosing-schedule-complete-guide): | Phase | Dose | Duration | |-------|------|----------| | Starting dose | 2.5mg weekly | 4 weeks | | First escalation | 5mg weekly | 4 weeks | | Second escalation | 7.5mg weekly | 4 weeks | | Third escalation | 10mg weekly | 4 weeks | | Fourth escalation | 12.5mg weekly | 4 weeks | | Maximum dose | 15mg weekly | Ongoing | The titration schedule exists to minimize GI side effects. Each dose increase should only happen if the current dose is well-tolerated and more weight loss or glycemic control is needed. Not everyone needs to reach 15mg. Many patients achieve their goals at 7.5mg or 10mg. For detailed guidance, see our [complete tirzepatide dosing guide](/guides/tirzepatide-dosing-schedule-complete-guide). ## Side Effects: Same Drug, Same Profile Because Mounjaro and Zepbound are the same molecule, their side effect profiles are identical. ### Common Side Effects (>10% of patients) - **Nausea** (most common, affects 12-33% depending on dose) - **Diarrhea** (12-21%) - **Decreased appetite** (expected therapeutic effect) - **Vomiting** (5-9%) - **Constipation** (6-11%) - **Abdominal pain** (5-8%) - **Indigestion/dyspepsia** (5-8%) ### Less Common but Notable - **Injection site reactions** (3-4%) - **Fatigue** (3-5%) - **Sulfur burps** (reported frequently in patient communities, less captured in trial data) - **Hair thinning** (associated with rapid weight loss, not the drug itself) ### Serious but Rare - **Pancreatitis** (rare; discontinue if severe abdominal pain occurs) - **Gallbladder events** (increased risk with rapid weight loss) - **Thyroid C-cell tumors** (observed in rodents; clinical relevance in humans uncertain) - **Hypoglycemia** (primarily when combined with insulin or sulfonylureas) For detailed side effect management strategies, see our [tirzepatide side effects guide](/guides/tirzepatide-side-effects-complete-management-guide). ## Pricing and Insurance: Where It Actually Gets Different This is where the Mounjaro vs Zepbound distinction matters most in practice. ### List Prices Both carry similar list prices: - **Mounjaro**: approximately $1,023/month - **Zepbound**: approximately $1,060/month But virtually no one pays list price. The real cost depends on your insurance coverage. ### Insurance Coverage Scenarios **Scenario 1: You have type 2 diabetes** - Mounjaro is more likely to be covered because it is FDA-approved for diabetes - Many commercial insurance plans and some Medicare Part D plans cover Mounjaro - Zepbound may not be covered because your diabetes is the primary diagnosis **Scenario 2: You need weight loss without diabetes** - Zepbound is the correct prescription because it is FDA-approved for obesity - Commercial insurance coverage for weight loss drugs is growing but still inconsistent - Many employers are adding GLP-1 weight loss coverage to their plans - Medicare does not currently cover weight loss medications (as of 2026) - Mounjaro could be prescribed off-label, but insurance is unlikely to cover it for weight loss **Scenario 3: You have both diabetes and obesity** - Either could potentially be prescribed - Mounjaro may offer better insurance coverage - Discuss with your prescriber which route optimizes your coverage ### Manufacturer Savings Programs Eli Lilly offers savings programs for both: - **Mounjaro Savings Card**: Eligible commercially insured patients may pay as little as $25/month - **Zepbound Savings Card**: Similar structure for eligible patients These programs significantly reduce out-of-pocket costs but have eligibility requirements and maximum benefit caps. They typically do not apply to patients with government insurance (Medicare, Medicaid, Tricare). ### The Compounded Alternative For patients without adequate insurance coverage, [compounded tirzepatide](/guides/mounjaro-zepbound-alternative-compounded-tirzepatide-guide) from licensed 503B pharmacies offers a more affordable option at $200-450/month. Compounded versions contain the same tirzepatide molecule and are legal when prepared by properly licensed facilities. This is the same active ingredient regardless of whether you would have chosen Mounjaro or Zepbound. ## Which Should You Choose? The decision tree is straightforward: ### Choose Mounjaro If: - You have a **type 2 diabetes diagnosis** - Your insurance covers **diabetes medications** but not weight loss drugs - Your primary treatment goal is **glycemic control** (with weight loss as a benefit) - Your doctor recommends it based on your **diabetes management plan** ### Choose Zepbound If: - Your primary goal is **weight management** - You do **not have type 2 diabetes** (or it is not your primary concern) - Your insurance **covers weight loss medications** - You want the prescription to clearly reflect **obesity treatment** for your records ### Consider Compounded Tirzepatide If: - Neither Mounjaro nor Zepbound is covered by your insurance - You are **paying out of pocket** and need a more affordable option - You are comfortable with [subcutaneous self-injection](/guides/how-to-inject-glp1-medications-guide) - You have a prescriber willing to order from a [compounding pharmacy](/oem) ## Practical Tips 1. **Check your insurance first.** Before your doctor writes a prescription, call your insurance or use their formulary lookup tool to see which one (if either) is covered and at what tier. 2. **Ask about prior authorization.** Both drugs often require prior authorization (PA). Your doctor's office can initiate this process, but it may take days to weeks. Start early. 3. **Explore all savings options.** Check Lilly's savings cards, GoodRx, and other discount programs. Some patients save thousands per year by combining manufacturer and pharmacy programs. 4. **Don't split hairs over the brand.** The drug is identical. Your choice should be driven entirely by coverage, cost, and the indication that matches your medical situation. 5. **If switching between them**, no dose adjustment is needed. Continue at whatever dose you were on. Just inform your pharmacist and prescriber. ## Combining with Other Treatments Whether you choose Mounjaro or Zepbound, the supportive strategies are the same: - **High-protein diet** (0.7-1g per pound of lean body mass) to preserve muscle during weight loss - **Resistance training** 2-3 times per week for the same reason - **Adequate hydration** — at least 64 oz of water daily - **[NAD+ supplementation](/guides/nad-injection-benefits-anti-aging-energy-recovery-guide)** — some patients add NAD+ for energy and cellular health during weight loss - **Regular lab monitoring** — including metabolic panel, lipids, and A1C every 3-6 months ## The Bottom Line Mounjaro and Zepbound are the same drug — tirzepatide — with the same dosing, same efficacy, and same side effects. The only differences are the FDA-approved indication (diabetes vs weight management) and how insurance companies categorize them. Your choice should be driven by your diagnosis and insurance coverage, not by the brand name. Whether the label says Mounjaro or Zepbound, you are getting one of the most effective weight management medications ever developed. If neither brand-name option is financially feasible, [compounded tirzepatide](/guides/mounjaro-zepbound-alternative-compounded-tirzepatide-guide) provides the same active ingredient at a fraction of the cost through licensed pharmacies. Regardless of which path you choose, combining medication with lifestyle changes — including [proper nutrition on GLP-1 medications](/guides/what-to-eat-on-glp1-medications-diet-guide) and regular exercise — delivers the best long-term outcomes. --- ## References - [SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). *New England Journal of Medicine*, 2022. - [SURPASS-1: Tirzepatide versus Placebo in Type 2 Diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2107519). *New England Journal of Medicine*, 2021. - [Mounjaro (tirzepatide) Prescribing Information](https://pubmed.ncbi.nlm.nih.gov/?term=Mounjaro+(tirzepatide)+Prescribing+Information). *Eli Lilly and Company*, 2024. - [Zepbound (tirzepatide) Prescribing Information](https://pubmed.ncbi.nlm.nih.gov/?term=Zepbound+(tirzepatide)+Prescribing+Information). *Eli Lilly and Company*, 2024.